All In Biotech

Investigational drug · Phase 3

JK-1201I

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Glioblastoma Multiforme (GBM), Small Cell Lung Cancer.

Phase 3

Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

5

Any phase or sponsor naming "JK-1201I"

First trial start

2022

Oct 31, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "JK-1201I", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Glioblastoma Multiforme (GBM)
  • Small Cell Lung Cancer

Approved drugs for the same conditions: Small cell lung cancer · Brain tumors (glioma) · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "JK-1201I" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Glioblastoma Multiforme (GBM)

  • pegargiminaseADI-PEG 20Phase 33 trials

    Polaris Group · Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma

  • CobolimabPhase 32 trials

    GSK · Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma

  • silevertinibBDTX-1535Phase 22 trials

    Black Diamond Therapeutics, Inc. · Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.